Lv1
50 积分 2025-11-12 加入
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
9个月前
已完结
25258 Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
9个月前
已完结
62370 Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial
10个月前
已关闭
皖公网安备34019202002308
